|Bid||6.49 x 1800|
|Ask||6.59 x 2200|
|Day's Range||6.49 - 6.76|
|52 Week Range||4.70 - 11.22|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -17.68% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! A look at the shareholders of Iterum Therapeutics plc (NASDAQ:ITRM)Read More...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...